StockpollyBeta
Get App
Popularity #1,129
PGEN · NASDAQ · Biotechnology

Precigen (PGEN)

Commercializes PAPZIMEOS while developing selected gene and cell therapies.

$7.32
vs last close−0.57 (−7.22%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue11111111352355
Cost of revenue232111121233
Gross profit0−1−10000−1232052
212224612129233136242630
Research & development121314161112101112757
Selling, general & administrative99910101112024182122
Other expenses00035060200000
Operating income−21−23−24−61−21−29−23−32−34−22−623
1−1010−39−325−112−2−2−3
Interest income111000111110
Interest expense000000001333
Other non-operating income−110−103−932−4111−1−10
Income before tax−20−33−24−60−24−20−54−27−146−24−820
Income tax expense000−200000000
Net income from continuing operations−20−33−24−59−24−20−54−27−146−24−820
Net income−20−33−24−59−24−20−54−27−146−24−820
EPS, basic−$0.08−$0.13−$0.10−$0.23−$0.09−$0.07−$0.18−$0.09−$1.10−$0.07−$0.03$0.06
EPS, diluted−$0.08−$0.13−$0.10−$0.23−$0.09−$0.07−$0.18−$0.09−$1.10−$0.07−$0.03$0.05
Weighted average shares, basic249249249252276293294296296313313357
Weighted average shares, diluted249249249252276293294296296313313414
EBITDA−18−32−22−59−23−19−54−27−145−19−423
Depreciation & amortization222211111110
EBIT−20−33−24−60−24−20−54−28−145−21−523